Haemochromatosis is most commonly due to the autosomal recessive inheritance of a C282Y substitution in the HFE protein,
Introduction
Haemochromatosis is a disease in which the absorption of dietary iron exceeds requirements. The disease is characterised by an inappropriate increase in intestinal iron absorption due to reduced expression of the iron regulatory protein, hepcidin. Left untreated, this can result in progressive iron overload and liver toxicity.
HFE-related haemochromatosis is by far the most common cause of primary iron overload and is associated with one major substitution in the HFE protein. This pCys282Tyr (C282Y) change is a result of a missense mutation in the HFE gene. With carrier rates between 10 and 15% among populations of Northern European ancestry, it is the most common mutation associated with a clinical disease. 1 The original mutation is thought to have arisen as a unique event more than 5000 years ago, from a nomadic people in what is now central Europe. 2 Several factors may have contributed to a high selection pressure to fix such a mutation in the population. Red meat, the only significant source of dietary iron, would have been consumed intermittently, as stone-age hunter-gatherers gave way to harvesters of cereal grains, high in carbohydrates but low in iron. In addition, the high-fertility rate saw women having multiple children, losing much blood and iron in the process and forcing a mutation that was protective against iron deficiency with minimal risk of clinical symptoms in heterozygote form. This selection pressure combined with the founder effect of a small initial population likely underlies the frequency of the mutation in certain regions today. While clinical iron overload is strongly associated with the autosomal recessive inheritance of two C282Y alleles, the penetrance of both elevated iron studies and clinical symptoms is incomplete. The frequency of a homozygous C282Y substitution has been reported to be 0.4% in European countries, although prevalence varies widely on a global distribution. 3 On the other hand, the incidence of iron overload-related disease in people carrying the homozygous mutation is less than 30% for men and 1% for women.
4 This is partly due to environmental factors, including physiological blood loss, as well as the interaction of other genetic factors.
5-7 Novel research 8-10 is exploiting next-generation sequencing techniques to identify these disease modifying-genes that may close the gap in knowledge about incomplete penetrance of the C282Y substitution. At present, a definitive test to determine whether a person with the homozygous C282Y substitution will develop clinical symptoms remains elusive. Despite this, mechanisms for early diagnosis and effective treatment allow people with hereditary haemochromatosis to live a normal life, where progression to clinical disease is highly preventable and life expectancy is comparable to a control population.
11,12

Role of genetic variation
The HFE gene was first identified by Feder and colleagues more than two decades ago after a prodigious and costly effort in positional cloning. 13 While mutations in this gene remain the most common cause of hereditary haemochromatosis (known as Type 1 or HFErelated haemochromatosis), 14 pathogenic mutations in other genes have since been discovered to cause or contribute to the disease (Table 1) . These include mutations in HJV and HAMP genes (coding for haemojuvelin and hepcidin respectively) in juvenile (Type 2) haemochromatosis, which present a more severe phenotype with a much earlier manifestation of the disease. Mutations in TFR2 (transferrin-receptor 2) (Type 3) and the Ferroportin 1 gene (Type 4) can also result in what is collectively referred to as non-HFE-related hereditary haemochromatosis. Non-hereditary haemochromatosis (acquired/ secondary haemochromatosis) is comparatively rare, but can occur in cases of excessive iron administration and absorption. For example, in patients with beta thalassaemia intermedia/major, regular blood transfusions are required, compounding the increased iron absorption due to anaemia.
The 845G-A polymorphism that results in C282Y homozygosity makes up between 80 and 90% of hereditary haemochromatosis cases. 15 C282Y heterozygotes (genetic carriers for haemochromatosis) may have mildly elevated iron studies but will not develop significant clinical disease unless major cofactors are present, notably heavy alcohol ingestion or steatohepatitis. Compound (p.Cys282Tyr/His63Asp) heterozygotes contain both the C282Y and p.His63Asp (H63D) variants due to mutations in different alleles of the HFE gene. Patients with this genotype rarely develop iron-overload disease, 16 although women of reproductive age may benefit from a reduced risk of iron deficiency. 17 Patients homozygous for the H63D substitution are no more likely to develop clinical disease than control populations, although may still present with an increase in serum ferritin (SF) level. 18 These comments regarding disease penetrance do not necessarily hold when significant cofactors are involved. Excessive alcohol consumption and obesity can affect the clinical outcomes of compound heterozygotes, leading to more severe presentation of disease at an earlier age. 19 Additionally, patients homozygous for C282Y are significantly more likely to experience liver injury given the presence of certain cofactors. Fletcher et al. 20 compared liver biopsy data for 224 C282Y homozygous patients, and found that those who consumed ≥60 g alcohol per day were almost nine times as likely to develop severe fibrosis or cirrhosis as those who drank less alcohol per day. This may be due to the cumulative hepatic oxidative effects of alcohol in addition to excess hepatocellular iron stores. Non-alcoholic fatty liver disease (NAFLD) may also be a key cofactor in hereditary haemochromatosis patients with advanced liver damage. In a study 21 of 214 patients with haemochromatosis (homozygous for C282Y) who had undergone liver biopsy prior to phlebotomy, steatosis was present in 41%, due to both higher body mass index and alcohol consumption. The presence of steatosis was independently associated with liver fibrosis, along with male sex, excess alcohol consumption, and hepatic iron content. Clearly, the clinical expression of haemochromatosis may be influenced by confounding factors that increase hepatocyte injury, including but not limited to excessive alcohol consumption and obesity.
Iron metabolism, biochemistry and pathophysiology
Dietary iron absorption is normally dependent on the body's current iron status. Due to the efficient mechanism by which iron is recycled by the body, dietary intake is absorbed only to compensate for loss and, to a limited extent, storage in the liver. When dietary iron is taken up by enterocytes from the lumen of the gastrointestinal tract, tissue ferritin binds and stores iron in the enterocyte, preventing it from directly entering the bloodstream. This is particularly important if body stores of iron are already high. Ferroportin allows iron to be transported out of the enterocytes, for release into plasma. Once in the plasma, iron is bound to transferrin and delivered to various organs, most notably bone marrow for haem synthesis, and the liver for storage. A hepatic peptide, hepcidin, is the key hormone involved in the regulation of iron absorption, and low production or insensitivity to hepcidin is the final common metabolic pathway in hereditary haemochromatosis. Hepcidin interacts with and inactivates the iron export protein ferroportin. This limits the amount of dietary iron entering the plasma from enterocytes, recycled iron from macrophages and stored iron from hepatocytes. Hepcidin production is regulated by the bioavailability of iron, so that hepcidin synthesis increases with increased iron storage in the liver, thus limiting further absorption of iron. Similarly, iron deficiency results in downregulation of hepcidin production by the liver, so that iron absorption can increase. In adult hereditary haemochromatosis, defective HFE or TFR2 genes result in a downstream deficiency of hepcidin, leading to excessive ferroportin expression at the cell surface. The resultant increased plasma iron and increased transferrin saturation (TS) leads to parenchymal iron excess. The exact mechanism by which the mutated HFE gene influences hepcidin production is not yet clear.
Clinical presentation, initial screening and diagnosis
Classically, hereditary haemochromatosis was characterised by the triad of bronze skin pigmentation, diabetes mellitus and liver cirrhosis. This was the portrait of the first reported case of haemochromatosis (diagnosed retrospectively) described by Trousseau in 1865. Due to increased awareness by clinicians and advances in diagnosis and treatment, such late presentations of the disease are now infrequent. 22 Moreover, the presence of diabetes and/or liver disease is rare if chronic excess alcohol consumption is excluded as a comorbid condition. Nowadays, the disease is frequently first recognised by elevated iron indices in one or both of SF and TS, the former exquisitely reflecting the level of total stored iron in the body. 23 Abnormal test results may be discovered through standard blood tests at a routine check-up. Importantly, the disease can be detected with or without the presence of any clinical symptoms, although lethargy is common prior to the development of advanced disease. 24 The natural history of untreated haemochromatosis is illustrated in Figure 1 .
The difficulty in diagnosing a patient with haemochromatosis lies in the broad way the disease can present clinically. While fatigue and arthralgias are the most common symptoms encountered early in the disease, [26] [27] [28] progressive liver injury with cirrhosis and hepatocellular carcinoma (HCC) are possible long-term consequences of severe iron overload. Symptoms usually develop earlier in men than women, most commonly in the fourth to fifth decades of life. In women, clinical symptoms usually appear post-menopause, due to iron Figure  1 Natural history of (untreated) hereditary haemochromatosis. Prompt diagnosis and treatment with phlebotomy ensure that progression of disease to organ damage in C282Y homozygotes is unlikely, unless environmental factors are involved (Adapted from Griffiths, loss during menstruation, pregnancy and lactation offsetting the increased absorption of iron during this time.
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With the non-specificity of clinical symptoms and incomplete penetrance of the HFE mutations, screening and ultimately diagnosis relies on health checks with specific blood tests, and an awareness of the prevalence of the disease in certain populations. An SF concentration above 300 μg/L in men and 200 μg/L in women is an early indication of the disease; however, the levels can fluctuate depending on the sex and age of the patient. SF may also be non-specifically elevated as an acute-phase reactant in common chronic conditions, including fatty liver disease, metabolic syndrome and other inflammatory diseases. 29 Thus, when using SF to measure accurately iron storage, it is important to consider the implications of other co-morbid diseases. In this situation, the percentage TS is helpful, as it is not elevated in fatty liver disease or metabolic syndrome. An elevated TS is often present in earlier stages of the disease than SF. 30 A threshold of 45% for serum TS when fasting is the most sensitive value for detecting the disease, but is less specific than a higher threshold. This is because patients heterozygous for the C282Y substitution or compound heterozygotes may show raised iron indices without developing clinical symptoms. Nevertheless, a high TS reliably indicates the possible presence of C282Y homozygosity, and should be followed by a genetic test for mutations in the HFE gene.
Family screening
After diagnosing a patient with hereditary haemochromatosis, particularly in relation to the C282Y substitution, it is the responsibility of the physician to ensure that the patient's first-degree family members are screened for the possibility of carrying the same mutation. While people homozygous for the C282Y variants can be asymptomatic over a lifetime, the likelihood of nuclear family members sharing a similar environment and potentially other relevant genetic markers with the index case may further increase the risk of developing clinical symptoms of iron overload. Children need not be screened until the age of 18, as for HFE-related haemochromatosis the disease rarely presents beforehand. 31 However, if SF is very high (>1000 μg/L), earlier testing is necessary and may reveal considerably rarer mutations in either the HJV or HAMP genes underlying juvenile haemochromatosis.
Further evaluation
Once C282Y homozygosity has been identified, along with a high percentage serum TS, the task remains to assess whether iron deposition has led to damage to parenchymal organs. Previous studies have suggested that patients with a SF of less than 1000 μg/L were not at risk of developing liver fibrosis or progression to cirrhosis, and hence a liver biopsy was not required. 32 Formerly the 'gold standard' test when diagnosing a patient with hereditary haemochromatosis, histological examination of a liver biopsy has become superfluous to genetic testing for C282Y homozygosity. On the other hand, a biopsy is recommended for patients whose blood tests indicate the possibility of liver disease, for example abnormal liver enzymes in the setting of a very high SF concentration (>1000 μg/L). 33 Transient elastography (FibroScan; Echosens, Paris, France) 34 is a useful noninvasive test for detecting significant liver fibrosis. A low liver stiffness measurement (<7 kPa) has a good negative predictive value for excluding significant fibrosis, and use of this test may remove the need for biopsy if liver enzymes are normal. Alternatively, the FibroScan may suggest the presence of significant fibrosis, and in this case a liver biopsy may be recommended.
The merit of less invasive techniques to measure liver iron content is a matter of current debate. Magnetic resonance imaging (MRI) can be used to assess the presence of elevated hepatic iron in a qualitative fashion, as MRI is sensitive to the presence of iron. More recently, quantitative assessment of liver iron content has been developed using MRI measurement and imaging of proton transverse relaxation rates within the liver. 35 FerriScan is an MRI-based technology that provides a reliable measure of liver iron content. The ability to assess the liver in full using MRI rather than a small biopsy sample reduces sampling variations, while avoiding the risks associated with an invasive procedure. 36 Currently, the technology is confined to certain diagnostic imaging departments. However, its accuracy, less invasive nature and the lower risk of procedural complications make it an attractive technique for future serial analyses of progressive iron overload or depletion.
An estimation of the amount of iron overload can also be obtained retrospectively by recording the number of phlebotomies required to normalise iron indices. A 500 mL venesection is estimated to remove 250 mg iron. This technique may be useful in patients who are reluctant to undergo liver biopsy. A diagnosis of haemochromatosis is likely if 4-5 g of iron is available for removal without the development of anaemia (equivalent to between 16 and 20 phlebotomies).
Treatment and management
Regular phlebotomy remains the first-line treatment for hereditary haemochromatosis. The removal of iron through the removal of blood prior to the development of cirrhosis allows patients to have a normal life expectancy, as well as a reduction in some or all symptoms associated with the disorder. 37 Improvements in overall wellbeing, including fatigue, liver function (pre-cirrhosis) and skin pigmentation, are most noticeable. On the other hand, if cirrhosis is already well established, it is generally considered irreversible. Controversially, serial biopsies can depict the liver tissue architecture evolving from frank, nodular cirrhosis to incomplete septal cirrhosis with less nodules or just scar tissue. Despite this, the architecture of the liver remains disturbed, and the risk of HCC is still high.
38 Thus, cirrhotic patients should undergo surveillance for HCC with 6 monthly liver ultrasound examinations. Arthritis and associated jointsymptoms are also largely unresponsive to therapy. 39 This could be due to most joint symptoms not in fact being related to haemochromatosis; however, an early age of onset and 'unusual' location of joint symptoms are associated with the disease. 26 The onset and endpoint of phlebotomy treatment remains controversial. Treatment should be tailored to the clinical scenario of the individual patient. Abnormal SF levels for a menstruating woman likely differ to that of a male if both age and weight are considered.
7 Most consensus statements or guidelines 28, 40 agree to initiate treatment early. Bardou-Jacquet et al. 41 suggest the potential benefit of early treatment in patients with SF concentrations between the upper limit of normal and 1000 μg/L. Due to confounders and the lack of a randomised clinical trial, the potential benefit of treatment for patients with a mild to moderate iron burden awaits validation. 42, 43 The presence of clinical symptoms is not a prerequisite for diagnosis or treatment.
Therapeutic phlebotomy typically involves the removal of one unit of blood (between 400 and 500 mL) once or twice a week depending on the amount of iron in the patient at diagnosis. This is continued until SF levels are reduced to <50 μg/L, 3,41 and maintenance phlebotomy is able to maintain SF between a desired range of 50-100 μg/L. 3, 40 Phlebotomy is a lifelong treatment, with patients continuing to require periodic phlebotomy after SF levels have fallen to the appropriate range. Physicians should continue to monitor TS in conjunction with SF, as elevated TS may persist independently of SF, leading to an increase in non-transferrin bound iron and a reduced quality of life despite therapeutic phlebotomy. 44 The periodicity of this treatment is a matter of balancing steady yet low SF without haemoglobin concentrations falling below 11-12 g/dL. 40 Thus, it is important not to overcompensate with treatment and run the risk of rendering a patient iron deficient.
Patients requiring serial phlebotomy can be referred to the Australian Red Cross Blood Service. The 'High Ferritin' app is an online resource allowing eligible patients with HFE-related iron overload to undergo therapeutic venesection at the Australian Red Cross Blood Service, subject to eligibility criteria. Since its implementation in early 2013, the app has improved the efficiency and cost-effectiveness of blood donation, while streamlining the referral process for appropriate venesection. The evidence-based admission process has resulted in a reduction in unnecessary venesections, as well as an increased number of HFE-related haemochromatosis patients being accepted for blood donation. 45 Iron chelation is the recommended therapy for patients with acquired iron-overload, for example in beta-thalassaemia, and may be used to treat people with haemochromatosis who are refractory to or unable to receive phlebotomy. Deferasirox (Exjade; Novartis, Basel, Switzerland) is an iron chelator administered daily as an oral tablet, and has proven effective in both cases of acquired and HFE-related iron overload. 46, 47 However, its expense precludes routine use in primary iron overload. It is available for use on the Pharmaceutical Benefits Scheme for secondary iron overload, where venesection is not possible. Proton pump inhibitors have also been shown to reduce iron absorption in patients with hereditary haemochromatosis, allowing for an increased time between phlebotomies and proving a valuable addition to standard therapy. 48, 49 In cases of late diagnosis when advanced stages of the disease are apparent, a severe decline in liver function or development of HCC may warrant assessment for liver transplantation. Transplantation establishes normal hepcidin production and prevents the recurrence of hepatic iron overload, 50 verifying hepcidin insufficiency as the primary defect in HFE-associated haemochromatosis and the liver as the sole organ involved in the primary genetic abnormality.
Diet
While patients with hereditary haemochromatosis possess genetic modifications that contribute to iron overload, there has been increasing interest in dietary factors that can alter iron absorption. Vitamin C in citrus fruits increases iron absorption by converting ferric iron into the preferentially absorbed ferrous form, 51 while polyphenols in tea and coffee (amongst other polyphenoliccontaining beverages) can reduce non-haem iron absorption when consumed together. 52 A 1990 study degree than men to maintain homeostasis. Incorporating these dietary factors into the ongoing management of the disease may influence long-term iron accumulation, although direct evidence is yet to support dietary interventions as an outright therapeutic strategy for people with haemochromatosis. 54 
Conclusions
While treatment for progressive iron overload has remained relatively unchanged over the past few decades, approaches to diagnosis and monitoring of disease have improved significantly (summarised in Fig. 2 ). Due to increased awareness of the range of clinical symptoms involved, the availability of a test for the HFE genetic mutation, and the different methods for measuring the degree of iron overload, patients with haemochromatosis are being diagnosed earlier. An early diagnosis is key to patient outcome, as prompt treatment with recurrent phlebotomy ensures that patients will avoid developing significant clinical disease and especially cirrhosis. Family screening also plays an important role in early diagnosis, given the Mendelian pattern through which HFE-related haemochromatosis is inherited. The presence of cirrhosis mandates screening for HCC, and the development of decompensated liver disease may warrant consideration for liver transplantation. Maintenance of a healthy body weight and level of physical activity is important to reduce the risk of developing comorbid liver disease, such as NAFLD. In general, alcohol intake should be limited to National Health and Medical Research Council guidelines (≤2 standard drinks on any day). In the presence of significant fibrosis or cirrhosis, alcohol intake should be avoided. Radford-Smith et al.
